Table 4. Summary of studies of patients with relapsed osteosarcoma.
| Author (study site) |
n | Study years | Inclusion criteria | Median months of follow-up |
Median age in years (range) |
CR2 | Lung only |
Chemo at RL1 |
Surgery at RL1 |
Post- relapse outcome |
Factors associated with PRS |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| Leary (St Jude) |
110 | 1970-2004 | RL after chemo, CR |
164 | 14 (6-25) | 56% | 75% | 46% | 76% | 10 years: PRS 17% PREFS 12% |
CR2, TTR ≥18 months, chemo in no CR2 (PREFS), unilateral lung |
| Crompton (UCSF)6 |
37 | 1974-1996 | extremity primary, PR or CR |
16 (5-31) | 60% of lung only |
68% | 68% | 62% | 10 years: PRS 15% PREFS 5% |
none | |
| Kempf- Bielack (Germany)8 |
576 | 1979-1998 | RL after chemo, CR |
50 | 16 | 59% | 65% | 69% | 74% | 10 years: PRS 18% |
CR2, TTR >18 months, chemo, solitary lesion |
| Bacci (Italy)1 |
235 | 1986-1998 | extremity primary, RL after neo-adjuvant chemo, CR |
mean 72 | 14 | 74% | 80% | 23% | 74% | 5 years: PRS 29% PREFS 28% |
TTR >24 months (PREFS), < 3 lung lesions metastases, treating institution |
| Chou (MSKCC)5 |
43 | 1990-2004 | RL after chemo including 3 active agents*, CR |
15 | 15 (5-31) | 60% | 51% | 91% | 81% | 3 years: PRS 35% PREFS 14% |
CR2, TTR>24 months |
| Hawkins and Arndt(Seattle/ Mayo Clinic)7 |
59 | 1990-2000 | RL after chemo, CR |
58 | 15 (5-23) | 68% | 61% | 64% | 79% | 4 years: PRS 23% PREFS 6% |
CR2, TTR>24 months unilateral lung RL, solitary lung nodule, |
| Saeter(Norway)9 | 60 | 1975-1993 | systemic RL after CR of extremity primary |
47% | 88% | 54% | 5 years: PRS 24% |
CR2, chemo, solitary lesion |
|||
| Tabone (France)10 |
42 | 1981-1993 | non-metastatic at diagnosis, RL after chemo |
39 | 12 (4-18) | 81% | 48% | 57% | 81% | 3 years: PRS 36% PREFS 27% |
CR2, local or lung RL, first relapse |
Chemo = chemotherapy; CR = complete remission; PR = partial remission; PREFS = post-relapse event-free survival; PRS = post-relapse survival; RL = relapse; TTR = Time to relapse
*
Active agents included high-dose methotrexate, cisplatin, doxorubicin, and ifosfamide